---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004635"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:34:01.617734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Harrow reaffirms 2025 revenue guidance of $270-280M, promotes Sullivan to CCO, settles CA regulatory matters

## Summary
- Reaffirmed FY2025 revenue guidance of $270-280 million; full-year results expected in early March.
- Patrick Sullivan promoted to CCO; $425k base salary, 40% target bonus, 40,000 RSUs vesting on $230M quarterly branded revenue.
- VEVYE sales force to double to ~100 territories by Memorial Day; TRIESENCE surgical sales force also doubling.
- ImprimisRx settled with CA Board of Pharmacy for ~$157k fine and voluntarily exited CA market; not financially material.
- MELT-300 NDA submission on track for H1 2027; MELT-210 NDA on track.

## SEC filing metadata
- accession: 0001493152-26-004635
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315226004635/0001493152-26-004635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315226004635/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004635
- JSON: https://secwatch.observer/filing/0001493152-26-004635.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.